Abstract:Despite significant improvements that have been made in terms of progression-free survival and overall survival rates brought about by targeted therapy in non-small cell lung cancer (NSCLC), the emergence of drug resistance remains a limiting factor. However, a previous study has shown promising results by combining local microwave ablation (MWA) with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy for patients with oligometastatic NSCLC. The current study presented the case of a Chinese female patient who was identified as having lung adenocarcinoma (LADC) with EGFR exon 19 deletions (Del) in January 2014, and who experienced multiple instances of oligoprogression but showed a positive response to a combination of chemotherapy, MWA and a TKI drug. First, the patient was treated with four cycles of chemotherapy (120 mg docetaxel on day 1 and 40 mg cisplatin on days 1, 2 and 3; every three weeks as one cycle) and gefitinib (Iressa; 250 mg/day), maintaining a partial response for 17 months. In August 2015, a new solitary lesion was identified in the right lung and erlotinib (Tarceva; 150 mg/day) was administered for 3 months thereafter. In response, the patient underwent ablation of both the new right lung lesion and the primary left lung lesion in January 2016. Subsequently, a treatment course consisting of six cycles of chemotherapy (0.8 g pemetrexed on day 1 and 70 mg nedaplatin on days 1 and 2; every three weeks as one cycle) resulted in stable disease. In May 2016, the patient began treatment with osimertinib (AZD9291; 80 mg/day), resulting in a rapid shrinkage of the mediastinal lymph node after one month, which has been providing a benefit for the patient for 82 months and counting. Of note, the patient also developed metachronous colon cancer in January 2020, followed by the identification of right posterior liver metastases in February 2020 and lung metastases in May 2021 and in February 2022. To address this, the patient underwent radical resection of colon cancer and liver metastasectomy and received a combination of chemotherapy with bevacizumab, along with MWA for lung metastases. Remarkably, the patient has achieved long-term survival of 110 months. In conclusion, this case highlights the promising potential of combining MWA with systemic therapy for a patient with advanced LADC harboring EGFR exon 19 Del and metachronous lung and liver-metastasized colon adenocarcinoma. MWA effectively controlled both in situ oligoprogression and new oligoprogression, thereby enhancing the efficacy of systematic chemotherapy/TKI therapy. Furthermore, this case report emphasizes the importance of repeated histologic biopsies and genetic testing as reliable indicators for adjusting treatment regimens. Physicians should also remain vigilant regarding the occurrence of secondary primary carcinomas, and timely and accurate adjustments to treatment plans will be of significant benefit to patients in terms of treatment efficacy and overall quality of life.

Microwave Ablation As Local Consolidative Therapy for Patients with Extracranial Oligometastatic EGFR-mutant Non-Small Cell Lung Cancer Without Progression after First-Line EGFR-TKIs Treatment

Microwave Ablation Combined with EGFR-TKIs Versus Only EGFR-TKIs in Advanced NSCLC Patients with EGFR-sensitive Mutations

Microwave Ablation in Combination with Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Percutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLC

Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer

Efficacy and Safety of Microwave Ablation in the Treatment of Patients with Oligometastatic Non-Small-cell Lung Cancer: a Retrospective Study.

Combination of microwave ablation and systemic treatments achieve a long survival time for a patient with metachronous advanced double primary lung and colon adenocarcinoma: A case report

Microwave Ablation for Non-Small Cell Lung Cancer with Synchronous Solitary Extracranial Metastasis

Microwave Ablation Plus Chemotherapy Improved Progression-Free Survival of Advanced Non-Small Cell Lung Cancer Compared to Chemotherapy Alone.

Microwave ablation combined with lipiodol-microsphere mixed or conventional transarterial chemoembolization for the treatment of colorectal liver metastases: A retrospective study

Multicentre Study of Microwave Ablation for Pulmonary Oligorecurrence after Radical Resection of Non-Small-cell Lung Cancer.

Microwave ablation treatment for medically inoperable stage I non-small cell lung cancers: long-term results

Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial

Advanced Non Small Cell Lung Cancer: Response to Microwave Ablation and EGFR Status

Camrelizumab Combined with Microwave Ablation Improves the Objective Response Rate in Advanced Non-Small Cell Lung Cancer

Repeated Percutaneous Microwave Ablation for Local Recurrence of Inoperable Stage I Nonsmall Cell Lung Cancer

A Study of Microwave Ablation for Small Cell Lung Cancer.

Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.

Percutaneous Microwave Ablation (mwa) Increased the Serum Levels of Vegf and Mmp-9 in Stage I Non-Small Cell Lung Cancer (Nsclc)

Microwave ablation enhances the systemic immune response in patients with lung cancer

Clinical study of microwave ablation combined with radiochemotherapy in the treatment of Stage Ⅲ peripheral non-small cell lung cancer